$PGC

Banc Funds Co. LLC Reduces Holdings in Peapack-Gladstone Financial Corporation $PGC

Banc Funds Co. LLC has significantly reduced its stake in Peapack-Gladstone Financial Corporation (NASDAQ:PGC) by 31.9% in the third quarter, now owning 315,099 shares valued at $8.697 million. Despite this reduction, other institutional investors like Aquatic Capital Management LLC, CWM LLC, Quantbot Technologies LP, and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased their positions, while Merit Financial Group LLC acquired a new stake. The article also notes recent insider selling by EVP Maureen Hemhauser and provides financial details, dividend information, and analyst ratings for PGC, which currently holds a "Moderate Buy" rating with an average target price of $39.33.

Original reporting
MarketBeat · MarketBeat
Published Mar 15, 2026, 8:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 15, 2026, 10:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Banc Funds Co. LLC Reduces Holdings in Peapack-Gladstone Financial Corporation $PGC — source image
Decision brief

The 30-second read

$PGCNeutralLow
01

Why it matters

The decrease in institutional holdings could signal caution among large investors, potentially impacting short-term stock performance.

02

Market read

The news indicates a cautious stance by institutional investors, which could influence short-term trading in PGC and similar regional banks.

03

What to watch

The insider selling by EVP Maureen Hemhauser could be offset by other insider buying or positive fundamental developments not captured in this news.

Timing: short-term (within 1 month)

Background

Banc Funds Co. LLC significantly reduced its holdings in PGC, a regional bank, by 31.9% in Q1, possibly reflecting strategic portfolio adjustments.

Company-level read

Ticker impact

$PGCNeutralMedium confidence
Context

The news concerns institutional trading activity and insider transactions related to Peapack-Gladstone Financial Corporation (PGC).

Expected impact

Potential short-term decline of 1-3% due to institutional selling, but long-term impact remains uncertain without additional fundamental data.

Evidence & confidence

The mixed actions by institutional investors and insider sales suggest cautious sentiment. The overall reduction in holdings by Banc Funds Co. LLC could exert some downward pressure, but increased holdings by other investors and stable analyst ratings mitigate this effect.

Market effects

The reduction in institutional holdings in PGC may reflect broader concerns in regional banking sectors, but the increase by other investors suggests resilience.

Limited; primarily affecting regional bank stocks with similar profiles.

negligible; the news pertains to a regional bank with limited global exposure.

Counterpoint

The reduction by Banc Funds Co. LLC may be part of routine rebalancing and not indicative of negative outlook.

Key entities

  • Banc Funds Co. LLC

    A major institutional investor that reduced its stake in PGC.

  • Peapack-Gladstone Financial Corporation

    A regional bank with a moderate buy analyst rating and a target price of $39.33.

  • Maureen Hemhauser

    EVP who engaged in insider selling recently.

Related articles

$PGCMed

PEAPACK GLADSTONE FINANCIAL CORP (PGC): Results of Operations and Financial Condition

PEAPACK GLADSTONE FINANCIAL CORP (PGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pgc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: Frank A. Cavallaro, SEVP and CFO Peapack-Gladstone Financial Corporation T: 908-306-8933 PEAPACK-GLADSTONE FINANCIAL CORPORATION REPORTS SECOND QUARTER FINANCIAL RESULTS Bedminster, N.J. – July 27, 2026 – Peapack-Glad

$LDOSMedAI 9/10

Leidos to support extended ARTEMIS airborne ISR mission for U.S. Army

Leidos (LDOS) won a $127M U.S. Army contract to extend ARTEMIS airborne ISR mission through 2027, with option years. The contract supports intelligence, surveillance, and reconnaissance operations in Europe and other regions. Leidos provides the aircraft, systems, and services. The contract aligns with Leidos' NorthStar 2030 strategy, expanding its Defense Tech and Mission & Digital Solutions portfolio.

$VRTXMedAI 8/10

Inaxaplin Shows Kidney Benefit In Additional Patient Groups As Vertex Completes Key Trial Enrollment

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b results for Inaxaplin in additional patient groups with APOL1-mediated kidney disease, showing reductions in kidney damage markers. The company completed enrollment in its Phase 2/3 AMPLITUDE trial, with interim results expected in early 2027. Inaxaplin was generally safe and well-tolerated. VRTX stock is up 2.88% at $525.18.